cytosine has been researched along with Diarrhea in 11 studies
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug." | 7.66 | Ulcerating enteritis associated with flucytosine therapy. ( Traube, J; White, CA, 1982) |
| "Glucose-galactose malabsorption (GGM) is a rare autosomal recessive disorder of intestinal transport of glucose and galactose, leading to watery diarrhea, dehydration, failure to thrive, or early death." | 3.72 | Nephrolithiasis in a child with glucose-galactose malabsorption. ( Blau, N; Santer, R; Slaveska, N; Tasic, V, 2004) |
| "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug." | 3.66 | Ulcerating enteritis associated with flucytosine therapy. ( Traube, J; White, CA, 1982) |
| "Diarrhea was the most common adverse event in patients receiving CMX001 at doses of 200 mg weekly or higher and was dose-limiting at 200 mg twice weekly." | 2.78 | CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. ( Boeckh, M; Brundage, TM; Godkin, S; Marty, FM; Momméja-Marin, H; Mullane, KM; Papanicolaou, GA; Robertson, AT; Rowley, SD; Vance, E; Winston, DJ, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marty, FM | 1 |
| Winston, DJ | 1 |
| Rowley, SD | 1 |
| Vance, E | 1 |
| Papanicolaou, GA | 1 |
| Mullane, KM | 1 |
| Brundage, TM | 1 |
| Robertson, AT | 1 |
| Godkin, S | 1 |
| Momméja-Marin, H | 1 |
| Boeckh, M | 1 |
| Ronchi, A | 1 |
| Doern, C | 1 |
| Brock, E | 1 |
| Pugni, L | 1 |
| Sánchez, PJ | 1 |
| Streiter, M | 1 |
| Malecki, M | 1 |
| Prokop, A | 1 |
| Schildgen, V | 1 |
| Lüsebrink, J | 1 |
| Guggemos, A | 1 |
| Wisskirchen, M | 1 |
| Weiss, M | 1 |
| Cremer, R | 1 |
| Brockmann, M | 1 |
| Schildgen, O | 1 |
| Miyamoto, K | 1 |
| Chakrabarti, G | 1 |
| Morino, Y | 1 |
| McClane, BA | 1 |
| Tasic, V | 1 |
| Slaveska, N | 1 |
| Blau, N | 1 |
| Santer, R | 1 |
| Kellermayer, R | 1 |
| Siitonen, HA | 1 |
| Hadzsiev, K | 1 |
| Kestilä, M | 1 |
| Kosztolányi, G | 1 |
| Breddemann, A | 1 |
| Läer, S | 1 |
| Schmidt, KG | 1 |
| Harjes, M | 1 |
| Adam, R | 1 |
| Ludwig, A | 1 |
| Niehues, T | 1 |
| Schneider, DT | 1 |
| Nicolasora, NP | 1 |
| Reddy, P | 1 |
| Kaul, DR | 1 |
| White, CA | 1 |
| Traube, J | 1 |
| Zincke, H | 1 |
| Furlow, WL | 1 |
| Farrow, GM | 1 |
| Seligman, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients[NCT00942305] | Phase 2 | 239 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary efficacy endpoint was a binomial outcome of failure to prevent cytomegalovirus (CMV) infection defined as CMV DNAemia >200 copies/mL obtained at the time of the last treatment with study drug or diagnosis of CMV disease at some point during the treatment phase. (NCT00942305)
Timeframe: Randomization to Week 8 post-treatment (~19 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 BCV | 13 |
| Cohort 1 Placebo | 4 |
| Cohort 2 BCV | 6 |
| Cohort 2 Placebo | 4 |
| Cohort 3 BCV | 12 |
| Cohort 3 Placebo | 4 |
| Cohort 4 BCV | 7 |
| Cohort 4 Placebo | 3 |
| Cohort 4a BCV | 5 |
| Cohort 4a Placebo | 7 |
1 review available for cytosine and Diarrhea
| Article | Year |
|---|---|
Neonatal adenoviral infection: a seventeen year experience and review of the literature.
Topics: Adenoviridae; Adenoviridae Infections; Age Factors; Antiviral Agents; Body Temperature; Cidofovir; C | 2014 |
1 trial available for cytosine and Diarrhea
| Article | Year |
|---|---|
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.
Topics: Administration, Oral; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Cytosine | 2013 |
9 other studies available for cytosine and Diarrhea
| Article | Year |
|---|---|
Does human bocavirus infection depend on helper viruses? A challenging case report.
Topics: Antiviral Agents; Cidofovir; Coinfection; Cytosine; Diarrhea; DNA, Viral; Helper Viruses; Herpesviru | 2011 |
Organization of the plasmid cpe Locus in Clostridium perfringens type A isolates.
Topics: Base Sequence; Blotting, Southern; Cloning, Molecular; Clostridium Infections; Clostridium perfringe | 2002 |
Nephrolithiasis in a child with glucose-galactose malabsorption.
Topics: Amino Acid Transport Systems, Basic; Chronic Disease; Codon, Nonsense; Cytosine; Diarrhea; Female; G | 2004 |
A patient with Rothmund-Thomson syndrome and all features of RAPADILINO.
Topics: Abnormalities, Multiple; Adenosine Triphosphatases; Amino Acid Substitution; Arginine; Bone and Bone | 2005 |
Case report: severe gastrointestinal inflammation and persistent HHV-6B infection in a paediatric cancer patient.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antiviral Agents; Astrocytoma; Cidofovir; Cytosine; | 2007 |
Biopsy-proven adenoviral diarrhea responding to low-dose cidofovir.
Topics: Adenoviridae; Adenovirus Infections, Human; Aged; Antigens, Viral; Antiviral Agents; Biopsy; Cidofov | 2008 |
Ulcerating enteritis associated with flucytosine therapy.
Topics: Aged; Amphotericin B; Biopsy; Cryptococcosis; Cytosine; Diarrhea; Flucytosine; Humans; Ileitis; Ileu | 1982 |
Candida albicans cystitis: report of a case with special emphasis on diagnosis and treatment.
Topics: Aged; Biopsy; Candida albicans; Candidiasis; Cystitis; Cystoscopy; Cytosine; Diarrhea; Female; Human | 1973 |
Letter: Treatment of vulval candidiasis with 5-fluorocytosine.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Cytosine; Diarrhea; Female; F | 1974 |